MAP kinase ERK1

Target ID: CHEMBL3385

Organism: Homo sapiens

Type: SINGLE PROTEIN

View on ChEMBL

Molecules

Name SMILES Bioactivity Structure
ABAMECTIN CC[C@H](C)[C@H]1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(C=C[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@]54O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O EC50: 12000.0 nM
GENISTEIN O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12 IC50: 1000.0 nM
FLUOCINOLONE ACETONIDE CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1 Potency: 35481.3 nM
INAMRINONE Nc1cc(-c2ccncc2)c[nH]c1=O Mean ED50: 0.389 mg kg-1
TANDUTINIB COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1 IC50: 26.0 nM
AMINOPHYLLINE Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN IC50: 16700.0 nM
6-METHOXY-2-NAPHTHYLACETIC ACID COc1ccc2cc(CC(=O)O)ccc2c1 Inhibition: 5.0 %
BOSUTINIB COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl IC50: 1.3 nM
VANDETANIB COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1 IC50: 900.0 nM
ERLOTINIB C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1 IC50: 1450.0 nM
RAF-265 Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21 Kd: 10000.0 nM
BUFLOMEDIL COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1 Ki: 60.0 nM
AMITRAZ Cc1ccc(/N=C/N(C)/C=N/c2ccc(C)cc2C)c(C)c1 Potency: 0.9 nM
AMPRENAVIR CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1 Ki: 0.16 nM
AMITRIPTYLINE CN(C)CCC=C1c2ccccc2CCc2ccccc21 IC50: 61.0 nM
AMPHOTERICIN B C[C@@H]1[C@H](O)[C@@H](C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@H]1C)C[C@H](O)[C@H]2C(=O)O MIC: 4000.0 ug.mL-1
ACETAZOLAMIDE CC(=O)Nc1nnc(S(N)(=O)=O)s1 Ki: 250.0 nM
CANTHARIDIN C[C@@]12C(=O)OC(=O)[C@]1(C)[C@H]1CC[C@@H]2O1 IC50: 160.0 nM
ATENOLOL CC(C)NCC(O)COc1ccc(CC(N)=O)cc1 Pc: 1000000.0 cm s-1
CARBIMAZOLE CCOC(=O)n1ccn(C)c1=S IC50: 10400.0 nM
ACLARUBICIN CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC IC50: 9900.0 nM
ANISINDIONE COc1ccc(C2C(=O)c3ccccc3C2=O)cc1 Inhibition: 1.3 %
AMINOCAPROIC ACID NCCCCCC(=O)O Ki: 50000.0 nM
BETADEX OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]1[C@H](O)[C@H]2O)O[C@@H]8CO)O[C@@H]7CO)O[C@@H]6CO)O[C@@H]5CO)O[C@@H]4CO)O[C@@H]3CO k_obs: 4.16e-07 s-1
BRIMONIDINE Brc1c(NC2=NCCN2)ccc2nccnc12 pC25: 1.55 uM kg-1
FLUCONAZOLE OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F IC80: 2.8 ug ml-1
AMIKACIN NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O C50: 0.21 uM
AST-487 CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1 Kd: 2.3 nM
RUBOXISTAURIN CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1 IC50: 300.0 nM
CANDESARTAN CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1 T1/2: 9.0 hr
ACETAMINOPHEN CC(=O)Nc1ccc(O)cc1 Vdss: 0.95 L.kg-1
EUCALYPTOL CC12CCC(CC1)C(C)(C)O2 MIC: 800.0 ug.mL-1
HALOPROGIN Clc1cc(Cl)c(OCC#CI)cc1Cl MIC: 3.13 ug.mL-1
AMPICILLIN CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O MIC: 5.0 ug.mL-1
CP-724714 COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 IC50: 12.0 nM
ALVOCIDIB CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1 IC50: 330.0 nM
AZARIBINE CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O Potency: 562.3 nM
ACEBUTOLOL CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1 LD50: 76.0 mg.kg-1
ASTROMICIN CO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN Hepatotoxicity (moderate): 7.3 %
BITHIONOL Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O Control current: 198.6 %
FLOXURIDINE O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F IC50: 2.0 nM
BETAMETHASONE PHOSPHORIC ACID C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O Inhibition: 96.0 %
AMOXICILLIN CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O MIC: 0.021 ug.mL-1
ACONITINE CCN1C[C@]2(COC)[C@H](O)C[C@H](OC)[C@@]34[C@@H]5C[C@@]6(O)[C@H](OC(=O)c7ccccc7)[C@@H]5[C@@](OC(C)=O)([C@@H]([C@H](OC)[C@H]23)[C@@H]14)[C@@H](O)[C@@H]6OC Activity: 160.0 bpm
AMIFOSTINE NCCCNCCSP(=O)(O)O LD50: 1049.0 mg.kg-1
ASTEMIZOLE COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1 Binding energy: 11.3 kCal mol-1
CAFFEINE Cn1c(=O)c2c(ncn2C)n(C)c1=O Vdss: 0.61 L.kg-1
ATROPINE CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2 Ki: 0.45 nM
MOTESANIB CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21 Kd: 1100.0 nM
SUNITINIB CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C IC50: 80.0 nM
AZD-1152-HQPA CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1 Ki: 10000.0 nM
QUERCETIN O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12 IC50: 32870.0 nM
AMILORIDE N=C(N)NC(=O)c1nc(Cl)c(N)nc1N Pc: 780000.0 cm s-1
AT-7519 O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl IC50: 47.0 nM
LINIFANIB Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1 IC50: 4.0 nM
LAPATINIB CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1 IC50: 10.0 nM
DOVITINIB CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1 IC50: 65.0 nM
TOFACITINIB C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12 IC50: 13.0 nM
CANERTINIB C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1 IC50: 74.0 nM
VATALANIB Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1 IC50: 37.0 nM
BMS-387032 CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1 IC50: 48000.0 nM
PAZOPANIB Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O IC50: 10.0 nM
CRIZOTINIB C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl IC50: 8.0 nM
AMINOPTERIN Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2n1 Ki: 0.0037 nM
ESTRADIOL C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O IC50: 1.5 nM
IMATINIB Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1 IC50: 40.0 nM
GEFITINIB COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 IC50: 515.0 nM
MLN-8054 O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1 Activity: 39.7 %
DORAMAPIMOD Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1 Kd: 0.046 nM
TOZASERTIB Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1 Ki: 0.6 nM
SELICICLIB CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1 IC50: 450.0 nM
PELITINIB CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C IC50: 83.0 nM
MIDOSTAURIN CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4 Kd: 11.0 nM
SORAFENIB CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1 IC50: 12.0 nM
SU-014813 Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1 Kd: 1.8 nM
NEFLAMAPIMOD O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl IC50: 22.0 nM

Top Fragments

SMILES Avg pKi Count Structure
[5*]N[5*] 7.5 1148
[3*]O[3*] 7.19 770
[1*]C([6*])=O 7.74 434
[16*]c1ccc([16*])cc1 8.2 400
[3*]OC 6.95 390